Mesoblast Announces Late Breaking Presentation at American Heart Association (AHA) annual Scientific Sessions of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure

Mesoblast Announces Late Breaking Presentation at American Heart Association (AHA) annual Scientific Sessions of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure

Mesoblast presented positive results from the phase 3 DREAM-HF trial evaluating rexlemestrocel-L in patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Trial results highlighted a reduction in cardiovascular mortality, heart attacks and strokes, with the greatest effect seen in the setting of inflammation, as quantified by high-sensitivity C-reactive protein (hs-CRP). The data were presented as a late breaking presentation at the American Heart Association (AHA) annual Scientific Sessions. 

DREAM-HF is a double blind, randomized, placebo-controlled trial in patients with chronic HF due to LV systolic dysfunction of either ischemic or nonischemic etiology who have received optimal medical/revascularization therapy.

The data were presented by the trial’s co-principal investigator Dr Emerson Perin, Medical Director of Texas Heart Institute, and Clinical Professor, Baylor College of Medicine. Key findings included the following: 

A single dose of rexlemestrocel-L on top of standard of care reduced the incidence of heart attacks or strokes by 65% across all 537 NYHA class II or class II...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee